Sign in

You're signed outSign in or to get full access.

PP

Praxis Precision Medicines, Inc. (PRAX)·Q2 2025 Earnings Summary

Executive Summary

  • Praxis reported a deeper investment phase tied to epilepsy programs, with Q2 2025 net loss of $71.1M and EPS of $(3.31), versus $(32.7M) and $(1.74) in Q2 2024 as R&D spending scaled for registrational studies .
  • RADIANT topline showed best‑in‑disease efficacy for vormatrigine: 56.3% median seizure reduction over eight weeks, ~60% achieving ≥50% response, and ~22% seizure‑free in the last 28 days; safety was generally favorable and discontinuations were largely manageable via background ASM dose adjustment .
  • Guidance sharpened: POWER1 on track to complete in Q4 2025 (previously “2H 2025”), POWER2 to initiate in Q3 2025 with a new 40 mg arm and mood endpoints, EMERALD (relutrigine) and EMBRAVE3 (elsunersen) initiated; cash runway into 2028 maintained .
  • Versus S&P consensus, Q2 EPS was a slight miss (actual −$3.31 vs consensus −$3.299*) and revenue came in at $0 vs ~$0.157M consensus*, reflecting the company’s pre‑commercial profile while R&D outlays rose for accelerated execution; EBITDA missed (actual −$76.0M* vs consensus −$68.7M*) as operating intensity increased. Values retrieved from S&P Global.
  • Near‑term stock catalysts: additional RADIANT data at the International Epilepsy Congress (Aug 31), POWER1 completion in Q4 2025, and regulatory tailwinds from July FDA Breakthrough Therapy Designation for relutrigine in SCN2A/SCN8A DEEs .

What Went Well and What Went Wrong

What Went Well

  • Vormatrigine delivered best‑in‑disease efficacy in RADIANT: 56.3% median seizure reduction; ~60% achieved ≥50% reduction; ~22% were seizure‑free in the last 28 days, with rapid onset and sustained benefit over eight weeks .
  • Safety/tolerability was manageable; adverse events were mostly mild/moderate and resolved, and discontinuations were mitigated when investigators reduced background ASMs per protocol guidance: “when done (6 patients) no discontinuation was observed” .
  • Strategic momentum: EMERALD (relutrigine) and EMBRAVE3 (elsunersen) registrational programs initiated; relutrigine granted FDA Breakthrough Therapy Designation enabling expedited development .

Management quotes:

  • “We…believe we are positioned to revolutionize treatment in both common and rare epilepsy…vormatrigine has shown an impressive 56.3% reduction in seizures in 8 weeks…” — Marcio Souza, CEO .
  • “We observed a median seizure reduction of over fifty six percent…sixty percent of patients achieved at least a fifty percent reduction…over twenty two percent…completely seizure free during the second month…” — Steven Petrou, CSO .

What Went Wrong

  • Operating intensity increased: R&D expenses rose to $63.0M (vs $27.3M YoY) as clinical programs scaled; net loss widened to $71.1M (vs $32.7M YoY) .
  • Discontinuation rate in the open‑label setting was 23%; while comparable to peers, the company aims to reduce it via clearer background ASM dose‑reduction guidance and study design refinements (e.g., POWER2 dose arm, mood endpoints) .
  • No Q2 collaboration revenue vs $0.357M in Q2 2024, reflecting lapsed service obligations after UCB’s KCNT1 option exercise; revenue de‑leveraging accentuated EBITDA loss .

Financial Results

Quarterly trend

MetricQ3 2024Q1 2025Q2 2025
Collaboration revenue ($USD Thousands)$302 $— $—
Research & development ($USD Thousands)$41,881 $60,806 $63,006
General & administrative ($USD Thousands)$15,256 $13,922 $13,061
Total operating expenses ($USD Thousands)$57,137 $74,728 $76,067
Net loss ($USD Thousands)$(51,910) $(69,296) $(71,127)
Net loss per share (basic & diluted, $USD)$(2.75) $(3.29) $(3.31)
Weighted avg shares (basic & diluted)18,884,562 21,055,834 21,474,827
Cash & investments at period end ($USD Thousands)$411,173 (168,645+242,528) $472,023 (165,567+306,456) $446,644 (157,415+289,229)

Q2 year-over-year

MetricQ2 2024Q2 2025
Collaboration revenue ($USD Thousands)$357 $—
Research & development ($USD Thousands)$27,260 $63,006
General & administrative ($USD Thousands)$10,585 $13,061
Net loss ($USD Thousands)$(32,677) $(71,127)
Net loss per share (basic & diluted, $USD)$(1.74) $(3.31)
Weighted avg shares (basic & diluted)18,824,479 21,474,827

Q2 actual vs S&P Global consensus

MetricActual Q2 2025Consensus Q2 2025
EPS (Primary, $USD)$(3.31) $(3.29915)*
Revenue ($USD)$0 $157,130*
EBITDA ($USD)$(76,021,000)*$(68,741,860)*

Values retrieved from S&P Global.

KPIs (RADIANT efficacy and safety, Q2 2025)

KPIQ2 2025
Median seizure reduction from baseline (%)56.3%
Patients achieving ≥50% seizure reduction (%)~60%
Patients seizure‑free in last 28 days (%)~22%
Discontinuation rate (%)23%
TEAEs (≥1) (%)59.0%
CNS‑related AEs (%)52.5%
Patients on cenobamate background (%)30%

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
POWER1 completion (vormatrigine, FOS)Q4 2025“2H 2025” topline On track to complete Q4 2025 Clarified timeline (maintained)
POWER2 initiation (vormatrigine, FOS)Q3 2025Initiate 2H 2025 Trial design completed; initiate Q3 2025 Clarified timing
POWER2 dose arm & endpointsQ3 2025N/AAdding 40 mg arm; include mood/depression endpoint New design elements
POWER3 monotherapy study1H 2026N/AExpected to initiate 1H 2026 New program detail
EMERALD registrational study (relutrigine)2025Initiate mid‑2025 Initiated Executed
EMBRAVE3 registrational study (elsunersen)2025On track to initiate mid‑2025 Initiated; Cohort 1 enrolling Executed
Cash runwayInto 2028Into 2028 Into 2028 Maintained
Regulatory2025N/AFDA Breakthrough Therapy Designation for relutrigine in SCN2A/SCN8A DEEs (July) Positive milestone

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024, Q1 2025)Current Period (Q2 2025)Trend
Recruitment/execution engineEMPOWER started; >1,000 patients; POWER1 initiated 99 screened; 61 dosed by July 25; strong site enthusiasm; POWER1 on track for year‑end completion Strengthening
Background ASM managementNot emphasized previouslyDiscontinuations (23%) linked to lack of ASM dose adjustment; reducing background ASMs avoided discontinuations Process improvement focus
Efficacy deepening over timeRADIANT topline expected mid‑2025 Rapid onset with increasing response through week 8; exposure‑response supports 40 mg arm Positive trajectory
Mood/quality‑of‑life endpointsNot mentionedAdding mood/depression endpoints to POWER2 based on patient‑reported benefits Added to design
Regulatory momentumEMBOLD cohort 2 to register; EMERALD planned EMERALD and EMBRAVE3 initiated; relutrigine received BTD Accelerating
Cash runwayInto 2027 in 2024; into 2028 in Q1 2025 Into 2028 reiterated Stable

Management Commentary

  • “Earlier today we reported the positive results from the RADIANT study…we plan to shortly initiate POWER2 as well as the POWER3 study…We remain well‑capitalized as we look ahead to an exciting second half of 2025.” — Marcio Souza, CEO .
  • “Vlmitrijene delivered a truly remarkable performance…median seizure reduction of over fifty six percent…sixty percent…achieved at least a fifty percent reduction…over twenty two percent…completely seizure free during the second month.” — Steven Petrou, CSO .
  • “We have concluded that it would be beneficial to add a dose arm of forty milligrams to the POWER two study…we decided to include a depression and moods endpoints to the POWER two design.” — Marcio Souza, CEO .

Q&A Highlights

  • Background therapy impact: Investigators who proactively reduced background ASMs avoided discontinuations; efficacy maintained or improved post‑reduction, supporting monotherapy conversion in POWER3 .
  • Efficacy kinetics: Rapid onset by week 1 with deepening through week 8; exposure‑response suggests potential for greater effect at higher dose (40 mg) and over 12 weeks in POWER1/2 .
  • Discontinuations/placebo: Open‑label setting and aggressive background regimens contributed; site quality and stabilized pre‑study seizure assessments expected to lower placebo rates in POWER1 .
  • Label differentiation: Mood endpoints and monotherapy strategy designed to enhance clinical and commercial positioning versus current adjunctive, multi‑ASM approaches .

Estimates Context

  • Q2 2025: Slight EPS miss (actual −$3.31 vs −$3.299*), revenue under consensus ($0 vs ~$0.157M*), EBITDA below consensus (actual −$76.0M* vs −$68.7M*), reflecting stepped‑up R&D . Values retrieved from S&P Global.
  • Forward estimates (pre‑commercial profile; subject to pipeline catalysts):
    • Q3 2025: EPS −$3.472*, revenue ~$59k*, EBITDA −$72.9M*; Q4 2025: EPS −$3.093*, revenue ~$239k*, EBITDA −$68.5M*; Q1 2026: EPS −$3.306*, revenue $0*, EBITDA −$81.8M*. Values retrieved from S&P Global.
  • Estimate implications: Post‑RADIANT strength and accelerated registrational execution may prompt higher R&D and opex trajectories near term, while de‑risking efficacy and recruitment could compress time to pivotal readouts; consensus models should reflect clarified POWER1 timing (Q4 2025), POWER2 design changes, and regulatory tailwinds (BTD) .

Forward consensus

MetricQ3 2025Q4 2025Q1 2026
Primary EPS Consensus Mean ($USD)−$3.47197*−$3.09314*−$3.30556*
Revenue Consensus Mean ($USD)$59,440*$239,010*$0*
EBITDA Consensus Mean ($USD)−$72,930,680*−$68,470,630*−$81,800,000*
Primary EPS – # of Estimates14.0*15.0*9.0*
Revenue – # of Estimates14.0*15.0*8.0*

Values retrieved from S&P Global.

Key Takeaways for Investors

  • RADIANT efficacy is a material de‑risking event for vormatrigine in focal epilepsy; the rapid and deepening response profile strengthens confidence in 12‑week pivotal designs (POWER1/2) .
  • Background ASM dose management is a controllable driver of tolerability and retention; expect operational refinements to lower discontinuations in registrational trials (reduce execution risk) .
  • POWER2 design tweaks (40 mg arm, mood endpoints) provide upside optionality for efficacy magnitude and label differentiation; monitor initiation in Q3 2025 and enrollment cadence .
  • Regulatory momentum (relutrigine BTD; EMERALD/EMBRAVE3 started) broadens catalysts into rare epilepsies; combined with cash runway into 2028, capital risk is mitigated near term .
  • Near‑term trading setup: anticipate incremental RADIANT data flow (Lisbon, AES) and POWER1 completion (Q4 2025) as key sentiment drivers; position sizing should consider continued opex intensity vs. program de‑risking .
  • Consensus models may need to lift opex/R&D assumptions while maintaining minimal revenue until partnering/commercial milestones; potential multiple expansion hinges on sustaining best‑in‑disease narrative and clean pivotal execution .
  • Watch for generalized epilepsy dataset and POWER3 monotherapy initiation as scope‑expansion signals; monotherapy success could unlock first‑line positioning and materially expand TAM .
Note: All quantitative values from documents include explicit citations. Values marked with * are retrieved from S&P Global.